• Cy5 maleimide (non-sulfonated): Practical Guide for Thiol La

  2026-05-27

  Cy5 maleimide (non-sulfonated) enables selective, high-contrast labeling of cysteine-containing proteins and peptides for fluorescence-based workflows. Its use is most appropriate where organic co-solvent compatibility is acceptable and site-specific thiol conjugation is required. It is not recommended for targets lacking accessible thiols or workflows demanding high aqueous solubility.

• Structural Determinants of Cyclosporin Variants in Mitochond

  2026-05-27

  Efimov et al. systematically compared cyclosporin B–E variants to Cyclosporin A, revealing that peptide backbone flexibility critically influences their ability to inhibit the mitochondrial permeability transition pore. Their findings clarify why subtle structural modifications can dramatically alter both membrane interactions and bioactivity, with implications for immunosuppression and mitochondrial research.

• Beclin1 Deficiency Mitigates DOX-Induced Liver Injury via Fe

  2026-05-26

  This study uncovers a pivotal role for Beclin1 in promoting both ferroptosis and autophagy during doxorubicin-induced liver injury. By demonstrating that Beclin1 knockdown and DHODH overexpression reduce hepatic oxidative stress and injury, the research highlights new potential targets for mitigating chemotherapy-related hepatotoxicity.

• RNAi Screen Links Vesicular Transport to SARS-CoV-2 Release

  2026-05-26

  Kerr et al. conducted an arrayed RNA interference screen to uncover host cell factors that facilitate SARS-CoV-2 release, with a focus on vesicle-mediated exocytic transport. Their identification of Rab11a-dependent pathways and demonstration that CDK9 inhibition can block viral egress provide new mechanistic insights for host-targeted antiviral strategies.

• Perifosine (KRX-0401): Advanced Insights for Apoptosis and R

  2026-05-25

  Explore how Perifosine (KRX-0401) uniquely advances apoptosis and radiation sensitization research through potent Akt/mTOR pathway inhibition. This article delivers a deeper mechanistic analysis and practical protocol guidance, setting it apart from prior reviews.

• Antimycin A4: ATP-Citrate Lyase Inhibitor for Metabolic Rese

  2026-05-25

  Antimycin A4 stands out as a dual-action ATP-citrate lyase inhibitor and mitochondrial respiratory chain blocker, empowering metabolic researchers to dissect lipid biosynthesis and energy pathways with unprecedented specificity. This article translates bench findings into optimized protocols, troubleshooting strategies, and advanced applications, drawing on peer-reviewed evidence and practical lab experience.

• Capsaicin in Experimental Pain Models: Protocols & Insights

  2026-05-24

  Capsaicin ((E)-Capsaicin) is the gold-standard for dissecting TRPV1-mediated pain and inflammation, now expanded as a precision tool for epigenetic and cancer research. This article details advanced workflows, troubleshooting, and actionable protocol enhancements using APExBIO’s high-purity Capsaicin.

• Dabigatran Etexilate: Novel Oral Anticoagulant and CYP3A Int

  2026-05-23

  Dabigatran etexilate, as reviewed in the reference study, represents a significant advance in oral anticoagulation by offering predictable, rapid thrombin inhibition without reliance on CYP3A-mediated metabolism. This innovation addresses key limitations of traditional anticoagulants and has important implications for drug-drug interaction research, particularly in the context of CYP3A inhibitor use.

• CH 223191: Translational Leverage for AhR Axis Discovery

  2026-05-22

  This thought-leadership article delves into the mechanistic and strategic value of CH 223191, a potent aryl hydrocarbon receptor antagonist, for translational researchers. Drawing on the latest insights from the microbiota–tryptophan–AhR–intestinal stem cell axis in ulcerative colitis, it highlights how CH 223191 enables disentangling complex pathways in environmental toxicology and regenerative medicine, and provides actionable protocol guidance and a forward-looking perspective on cross-domain applications.

• Nicotinamide Riboside Chloride in Precision Neurodegenerativ

  2026-05-22

  Explore how Nicotinamide Riboside Chloride (NIAGEN) empowers translational researchers to advance neurodegenerative disease modeling—specifically retinal ganglion cell (RGC) degeneration—by bridging NAD+ metabolism, energy homeostasis, and reproducible stem cell differentiation. This thought-leadership article delivers a strategic, evidence-driven roadmap for integrating APExBIO’s high-purity NIAGEN into cutting-edge workflows and highlights both mechanistic rationale and workflow optimization, while situating these insights within the competitive and translational landscape.

• Tamoxifen in Research: Protocol Optimization & Use-Case Insi

  2026-05-21

  Tamoxifen’s versatility as a selective estrogen receptor modulator sets the benchmark for gene knockout, cancer, and antiviral workflows. This guide translates the latest reference findings and expert protocols into actionable, reproducible strategies for advanced biological research.

• Palbociclib (PD0332991): Precision Tools for Cell Cycle Arre

  2026-05-21

  Palbociclib (PD0332991) Isethionate enables reproducible, selective cell cycle G0/G1 arrest across diverse cancer models—crucial for dissecting proliferation, apoptosis, and resistance mechanisms. This guide translates reference-backed insights and troubleshooting strategies into actionable workflows for breast cancer and RCC research, maximizing translational impact.

• MG-132: Precision Proteasome Inhibition for Translational Re

  2026-05-20

  This thought-leadership article unpacks the mechanistic basis and translational strategies surrounding MG-132 (Z-LLL-al), a potent peptide aldehyde proteasome inhibitor. By bridging insights from protein turnover, oxidative stress, and apoptosis pathways, and drawing on recent cross-domain evidence from plant and cancer biology, we offer protocol recommendations, workflow optimization, and a forward-looking perspective for researchers pursuing targeted interventions in disease models.

• BMAL1 Phase Separation Orchestrates Circadian Transcription

  2026-05-20

  The reference study uncovers a mechanism whereby BMAL1, a core circadian clock protein, utilizes phase separation to form dynamic nuclear condensates that coordinate rhythmic gene expression. This work provides a new molecular framework for understanding oscillatory transcription and highlights the role of protein phosphorylation in modulating BMAL1's regulatory activity.

• WEHI-539: BCL-XL Inhibitor for Precision Apoptosis Research

  2026-05-19

  WEHI-539 stands out as a potent and selective BCL-XL inhibitor, empowering researchers to dissect apoptotic signaling and overcome chemoresistance in cancer models. This article delivers actionable protocols, troubleshooting insights, and synthesizes cutting-edge advances—such as synthetic lethality with Mcl-1 targeting—translating bench breakthroughs into workflow-ready guidance.

16286 records 1/1086 page Next 12345 下5页 Last page